ErbB signaling pathway
When epidermal growth factor (EGF) and its relatives bind the ErbB family of receptors, they trigger a rich network of signalling pathways, culminating in responses ranging from cell division to death, motility to adhesion.
Signalling through the ERBB/HER receptors is intricately involved in human cancer and already serves as a target for several cancer drugs.
Pathology
cancer
Therapeutics
over 25,000 women with breast cancer have now been treated with trastuzumab (Herceptin), a recombinant antibody designed to block the receptor ErbB2.
small-molecule enzyme inhibitors
monoclonal antibodies to ErbB1
References
Citri A, Yarden Y. EGF-ERBB signalling: towards the systems level. Nat Rev Mol Cell Biol. 2006 Jul;7(7):505-16. PMID: 16829981
de Bono JS, Rowinsky EK. The ErbB receptor family: a therapeutic target for cancer. Trends Mol Med. 2002;8(4 Suppl):S19-26. PMID: 11927283
Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001 Feb;2(2):127-37. PMID: 11252954